Discovery of the Novel Entecavir‐Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis

Entecavir (ETV) is a first‐line therapy for chronic hepatitis B virus (HBV), demonstrating potent suppression of HBV DNA and a high barrier to viral resistance. Previous studies revealed that ETV‐resistant (ETVr) HBV DNA resulted from substitutions in the HBV reverse transcriptase (RT) at positions...

Descripción completa

Detalles Bibliográficos
Autores principales: Rose, Ronald E., Hernandez, Dennis, Falk, Paul J., Ericson, Karen, Zhou, Nannan, Thiry, Alexandra, McPhee, Fiona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128232/
https://www.ncbi.nlm.nih.gov/pubmed/30202825
http://dx.doi.org/10.1002/hep4.1231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128232/
https://www.ncbi.nlm.nih.gov/pubmed/30202825
http://dx.doi.org/10.1002/hep4.1231

Ejemplares similares